Hospital admission (exacerbation) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (exacerbation) compared with tiotropium alone (low certainty).
1 finding from 1 review
Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with tiotropium alone (low certainty).
1 finding from 1 review
Change in baseline trough FEV1 · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Change in quality of life · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life SGRQ responder analysis at 6 months · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium probably leads to higher quality of life SGRQ responder analysis at 6 months compared with long‐acting beta2‐agonist alone (moderate certainty).
1 finding from 1 review
Hospital admissions · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (all cause) compared with long‐acting beta2‐agonist alone (moderate certainty).
1 finding from 1 review
Change in baseline trough FEV1 · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
1 finding from 1 review
All‐cause serious adverse events · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower all‐cause serious adverse events compared with ipratropium (high certainty).
1 finding from 1 review
Hospital admissions · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium probably leads to lower hospital admissions (all‐cause) compared with ipratropium (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium showed no clear difference in mortality (all‐cause) compared with ipratropium (moderate certainty).
1 finding from 1 review
Quality of life ( · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
1 finding from 1 review
Exacerbations · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower patients with one or more exacerbations compared with ipratropium (high certainty).
1 finding from 1 review
Treatment withdrawal · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower withdrawals compared with ipratropium (high certainty).
1 finding from 1 review
Intervention not reported
Exercise capacity · patients with pulmonary hypertension secondary to systemic scleroderma.
1 finding from 1 review
no estimate extracted
67 participants
Very low
Intervention not reported
WHO/NYHA functional class · patients with pulmonary hypertension secondary to systemic scleroderma.
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in number of participants experiencing at least 1 exacerbation… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Serious adverse events Adverse events · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in serious adverse events Adverse events compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Mortality Deaths · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in mortality Deaths compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Indacaterol leads to higher number of participants with a clinically significant improvement in… compared with placebo (high certainty).
1 finding from 1 review